ADMA Biologics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ADMA research report →
Range $18 – $21
Price Chart
About the company
ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally.
- CEO
- Adam S. Grossman
- IPO
- 2013
- Employees
- 644
- HQ
- Ramsey, NJ, US
Get TickerSpark's AI analysis on ADMA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.92B
- P/E
- 16.67
- Fwd P/E
- 16.41
- PEG
- -1.81
- P/S
- 5.63
- P/B
- 6.72
- EV/EBITDA
- 11.88
- Div Yield
- 0.00%
- Gross Margin
- 68.53%
- Op Margin
- 44.93%
- Net Margin
- 35.14%
- ROE
- 42.56%
- ROIC
- 28.23%
Latest fiscal year · YoY change
- Revenue
- $510.17M+19.6%
- Gross Profit
- $292.76M+33.3%
- Op Income
- $191.44M
- Net Income
- $146.93M-25.7%
- EPS
- $0.62-27.1%
- OCF Growth
- -57.5%
- FCF Growth
- -74.7%
- 52W High
- $20.46
- 52W Low
- $7.21
- 50D MA
- $10.97
- 200D MA
- $10.64
- Beta
- 0.77
- RSI (14)
- 62
- Avg Volume
- 3.23M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
ADMA delivered strong Q3 growth and margin expansion, led by accelerating ASCENIV demand, while lifting full-year EBITDA and net income guidance and keeping revenue guidance intact.· November 4, 2026
- ASCENIV was the clear growth engine: revenue reached $124.7 million, up 31% year over year and 21% sequentially.
- Total revenue was $141.1 million, up 5% year over year and 13% sequentially, with gross margin expanding to 71% from 56% a year ago.
- Adjusted EBITDA rose to $77.3 million and GAAP net income to $49.9 million, both showing strong operating leverage.
- Management raised full-year 2026 minimum adjusted EBITDA guidance to at least $275 million and adjusted net income guidance to at least $180 million, while reiterating revenue of at least $530 million.
- BIVIGAM remained pressured by pricing and channel competition, though management said utilization showed signs of stabilization into Q4.
Third-quarter 2026 revenue totaled $141.1 million, up 5% year over year from $134.2 million and up 13% sequentially from $124.4 million. ASCENIV revenue was $124.7 million, up 31% year over year and 21% sequentially; BIVIGAM revenue was $15.4 million versus $23.8 million a year ago and $19.4 million in Q2. Gross profit was $99.9 million versus $75.6 million a year ago, and gross margin was 71% versus 56% a year ago and 69% in Q2. Adjusted EBITDA was $77.3 million, up 32% year over year and 25% sequentially; GAAP net income was $49.9 million, up 37% year over year; GAAP basic EPS was $0.22 and adjusted basic EPS was $0.23. For the first 9 months, adjusted EBITDA was $198.8 million, cash from operations was $105 million, cash and cash equivalents were about $124.6 million, and total stock repurchases were $181.4 million with 16.5 million shares repurchased year to date. Full-year 2026 guidance was reiterated for revenue of at least $530 million, while minimum adjusted EBITDA was raised to at least $275 million from $265 million and minimum adjusted net income was raised to at least $180 million from $170 million.
Adam Grossman said the quarter reflected two themes: accelerating ASCENIV demand and the company’s ability to turn commercial momentum into earnings growth. He emphasized broadening physician adoption, new patient starts, favorable pull-through, and a growing evidence base as the main drivers of ASCENIV’s strength, and he framed the product as still early in its penetration curve. On BIVIGAM, he was more cautious, citing ongoing competitive pricing pressure but saying utilization is stabilizing and that scientific differentiation could improve positioning over time. He also highlighted SG-001 as a potential long-term growth opportunity and said recent FDA feedback was constructive.
Terry Kohler focused on the financial upside from mix and execution. He cited gross profit of $99.9 million, gross margin of 71% and about 1,450 basis points of year-over-year margin expansion, with favorable ASCENIV mix and yield-enhanced manufacturing as the main drivers. He said adjusted EBITDA reached $77.3 million, GAAP net income was $49.9 million, and adjusted basic EPS was $0.23, underscoring operating leverage. On capital allocation, he noted $124.6 million in cash, net leverage under half a turn, $181.4 million of stock repurchases in the first 9 months, and 16.5 million shares repurchased year to date. He also flagged accounts receivable of $169.2 million and DSOs of 110 days, above the 90 to 105 day target, while saying receivables are being collected and the company expects to work DSOs back down.
Analysts pressed on what drove the ASCENIV rebound, whether growth was still supported by new prescribers and patient starts, and whether secondary immunodeficiency and the McKesson relationship were contributing meaningfully. Management said the main driver remains primary immunodeficiency, while secondary immunodeficiency remains an opportunity that is progressing more slowly than hoped; they also said ASCENIV is largely insulated from the oversupply issues affecting standard IG. Questions on DSOs and McKesson drew a response that higher receivables were mainly due to the revenue mix, that collections remain strong, and that McKesson should help over time but is not expected to materially change DSOs in the rest of 2026. On SG-001, management said FDA feedback was encouraging, that an IND filing should come as soon as practicable but timing is not yet guided, and that Q4 R&D should step up to close to $10 million due to additional plasma and manufacturing costs.
The call’s bull case is that ASCENIV appears to be accelerating with more prescribers, new starts, and durable patient retention, and management believes the product still has a long runway ahead. The company is also generating strong cash flow and expanding margins, while returning capital through repurchases and raising profit guidance for the year.
The main bear case is that BIVIGAM remains under pressure from aggressive pricing and competition, and management does not expect the standard IG market to broadly recover soon. DSOs increased to 110 days, above target, and SG-001 will require more spend in Q4 with no firm IND timing yet, so near-term execution and capital demands remain relevant risks.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 95.7%
- Shares Outstanding
- 221.85M
- Float Shares
- 212.30M
of shares held by institutions
341 13F filers
Buy/sell ratio 0.38. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 37.31M | ▼ 1.05M |
| Vanguard Group Inc | 20.85M | ▼ 120.33K |
| State Street Corp | 13.68M | ▼ 3.44M |
| Rubric Capital Management LP | 12.35M | ▲ 3.01M |
| First Trust Advisors LP | 10.04M | ▲ 2.24M |
| Vanguard Capital Management LLC | 9.47M | ▼ 635.61K |
| Vanguard Portfolio Management LLC | 9.21M | ▼ 881.31K |
| Capital Research Global Investors | 8.75M | ▼ 7.37K |
| Geode Capital Management, LLC | 5.92M | ▼ 144.38K |
| Caligan Partners LP | 5.88M | ▲ 150.00K |
| D. E. Shaw & Co., Inc. | 5.64M | ▲ 363.81K |
| Dimensional Fund Advisors LP | 3.54M | ▼ 61.61K |
Held by 428 ETFs
Biggest fund positions in ADMA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 16, 26 | Guiheen Lawrence P. | other | 10,000 |
| Nov 16, 26 | Guiheen Lawrence P. | sell | 10,000 |
| Nov 16, 26 | Guiheen Lawrence P. | other | 10,000 |
| Nov 16, 26 | Grossman Adam S | other | 15,000 |
| Nov 16, 26 | Grossman Adam S | sell | 15,000 |
| Nov 16, 26 | Grossman Adam S | sell | 6,000 |
| Nov 16, 26 | Grossman Adam S | other | 15,000 |
| Nov 5, 26 | Grossman Adam S | other | 105,000 |
| Nov 5, 26 | Grossman Adam S | sell | 105,000 |
| Nov 5, 26 | Grossman Adam S | sell | 42,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ADMA coverage
Recent articles, reports, and earnings notes.
No research on ADMA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ADMA report →Here's Why Adma Biologics (ADMA) is a Strong Momentum Stock
zacks.com · Nov 13
Why Adma Biologics (ADMA) is a Top Growth Stock for the Long-Term
zacks.com · Nov 11
ADMA Surges 20.9% Post Q3 Earnings: Buy, Sell or Hold the Stock?
zacks.com · Nov 11
Adma Biologics (ADMA) Just Overtook the 20-Day Moving Average
zacks.com · Nov 6
Adma Biologics (ADMA) Recently Broke Out Above the 200-Day Moving Average
zacks.com · Nov 6
ADMA Biologics, Inc. (ADMA) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 5
Adma Biologics (ADMA) Q3 Earnings and Revenues Beat Estimates
zacks.com · Nov 4
ADMA Biologics Q3 Earnings Call Highlights
marketbeat.com · Nov 4
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.